Market News & Trends
Trius & Bayer Form Strategic Collaboration
Trius Therapeutics, Inc. and Bayer Pharma AG recently announced they have signed an exclusive agreement to develop and commercialize Trius' lead Phase III antibiotic, torezolid…
8/9/2011
Celgene & Acceleron Enter Agreement Worth Up to $242 Million Celgene Corporation and Acceleron Pharma, Inc. recently announced they have entered into a joint…
Amarin Successfully Completes All Remaining Clinical Studies for NDA
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, recently announced the successful completion of all remaining studies required for the…
Baxter Oncology Establishes Baxter Ventures; Will Commit $200 Million in Early Stage Companies
Baxter International Inc. recently announced it has established Baxter Ventures to invest up to $200 million in equity in promising early stage companies developing therapies…
Celgene & Acceleron Enter Agreement Worth Up to $242 Million
Celgene Corporation and Acceleron Pharma, Inc. recently announced they have entered into a joint development and commercialization agreement for ACE-536 for the treatment of anemia.…
Ironwood & Depomed Announce Collaboration, Research & License Agreement
Ironwood Pharmaceuticals, Inc. and Depomed, Inc. recently announced that Ironwood has licensed worldwide rights to utilize Depomed's Acuform gastric-retentive drug delivery technology for an Ironwood…
Sunshine Biopharma Looking to Mimic Roche's Billion-Dollar Cancer Drug
Last year, over 260,000 new cases of breast cancer (invasive and in situ combined) were diagnosed in women in the US. Over the course of…
Acorda Therapeutics Announces Initiation of Phase I Clinical Trial in Patients With Heart Failure
Acorda Therapeutics, Inc. recently announced the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating…
Apricus Biosciences Files Marketing Application for Vitaros
Apricus Biosciences, Inc. recently announced its filing of a marketing application for Vitaros as a treatment for patients with erectile dysfunction (ED) in Switzerland, with…
Daiichi Sankyo Launches Direct Oral Factor Xa Inhibitor
Daiichi Sankyo Launches Direct Oral Factor Xa Inhibitor Daiichi Sankyo Company, Limited recently announced the launch of LIXIANA (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban) in…
Hemispherx Biopharma Receives New Patent for Intranasal Ampligen
Hemispherx Biopharma, Inc. recently announced the granting of a new United States Patent for the use of Ampligen as a vaccine adjuvant for use with…
Unilife Commences Initial Supply of the Unifill Syringe to Sanofi
Unilife Corporation recently announced it has commenced the initial supply of validated product of the Unifill syringe to Sanofi, as per the terms of the…
7/26/2011
Daiichi Sankyo Launches Direct Oral Factor Xa Inhibitor Daiichi Sankyo Company, Limited recently announced the launch of LIXIANA (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban) in…
7/19/2011
Catalent & Sanwa Announce Exclusive License Agreement Catalent Pharma Solutions and Sanwa Kagaku Kenkyusho Co., Ltd. have recently entered into an exclusive agreement to bring…
Catalent & Sanwa Announce Exclusive License Agreement
Catalent Pharma Solutions and Sanwa Kagaku Kenkyusho Co., Ltd. have recently entered into an exclusive agreement to bring Sanwa's innovative drug delivery tableting technology to…
Generex Publishes Studies Confirming & Extending the Antigen Express Ii-Key Platform Technology
Generex Biotechnology Corporation recently announced the publication of studies conducted at the Mayo Clinic using the Antigen Express proprietary Ii-Key technology. Antigen Express, Inc., the…
Life Technologies Develops Potent Drug Delivery Technology for Therapeutics Market
Life Technologies corporation recently announced it has developed new drug delivery technology specially designed for therapeutic applications that is 100-fold more potent than previous formulations.…
Particle Sciences & Absorption Systems Form Relationship for Enhanced Services
Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, and Absorption Systems, a leading provider of preclinical pharmacokinetic services, recently announced the two companies are working…
QRxPharma Announces NDA Filing
QRxPharma Limited recently announced initiation of the NDA approval process for MoxDuo IR with the US FDA. This NDA submission sets the stage for the…
Zogenix & DURECT Announce Agreement for Antipsychotic Product Candidate
Zogenix, Inc., a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, and DURECT Corporation, a specialty pharmaceutical…
